By Beth Snyder Bulik
The Department of Health and Human Services plans to spend $250 million in media communications to “defeat despair and inspire hope” around the coronavirus pandemic, Politico reports. In a document sent to potential bidders, the agency detailed plans for a broad campaign across media and channels.
read more
By Robert King
Cleveland clinic posted a $241 million operating loss in the first half of the year, the latest system to post losses due to the pandemic.
read more
By Nick Paul Taylor
Vir Biotechnology and GlaxoSmithKline have begun dosing patients with a COVID-19 antibody in a phase 2/3 clinical trial. The study, which is expected to deliver data this year, is assessing whether the drug can prevent the hospitalization of high-risk patients recently infected with the coronavirus.
read more
By Eric Sagonowsky
In yet another hit for IL-6 inhibitors in coronavirus treatment, Sanofi and Regeneron's Kevzara failed a study in hundreds of severe and critical patients. The partners are now pulling the plug on further COVID-19 research featuring that rheumatoid arthritis med, focusing instead on their individual vaccine and antibody projects.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Sanofi and Regeneron quit research on Kevzara in COVID-19 after a phase 3 flop. Actemra sped up patients' recovery in a small study from Osaka University. COVAXX is developing a B- and T-Cell shot slated to enter human testing this summer. Plus, viral vector immunity could hamper the effects of Russia and Cansino's vaccines.
read more
By Robert King
New York-based hospital system Northwell Health estimates it has lost $1.1 billion due to the pandemic, and more losses could be on the way as patient volumes stagnate.
read more
By Angus Liu
Regeneron and recently signed-on partner Roche, with additional help from the National Institutes of Health, are leading the global race to develop antibody programs against COVID-19. By one analyst’s estimate, their candidate alone could bring in more sales next year than what Regeneron recorded for all of its products in 2019.
read more
By Amirah Al Idrus
Nocion Therapeutics has a new chief medical officer, and not a moment too soon. Christopher Silber, M.D., arrives as the company pushes its first program into the clinic: an inhaled treatment for chronic and acute cough that could come in handy against COVID-19. Suppressing coughs could help curb the spread of the disease, while also treating a symptom that can be debilitating.
read more
By Paige Minemyer
While a number of studies aim to estimate the impact of COVID-19, the full extent of any coverage losses will likely not be understood until next year, a new analysis shows.
read more
By Kyle Blankenship
After a wave of supply deals, British drugmaker AstraZeneca is working to secure enough capacity to meet what could be a 3 billion-dose demand for its COVID-19 vaccine front-runner. To hit that lofty goal, AstraZeneca needs partners—and the company is tightening its embrace with one of them to help keep up.
read more